

Professor Anthony M Lynch,
Global Director, Genetic Toxicology
GlaxoSmithKline R&D, Ware, UK.



Prof. Lynch graduated in Genetics & Zoology from the University of Wales, Swansea and obtained a PhD in Genetic Toxicology under Prof. J. Parry (former Chair of COM). His postdoctoral training was with Prof. D. S. Davies & Prof. A. R. Boobis at the Royal Postgraduate Medical School, Hammersmith Hospital, London (now Imperial College School of Medicine) where his research focused on molecular carcinogenesis and the application of transgenic models of mutagenesis. He was recruited by SmithKline Beecham (now GlaxoSmithKline) to set up a transgenic research laboratory in Genetic Toxicology. He is now Global Director of Genetic Toxicology – a unit that provides GSK with a Worldwide Centre of Excellence in the discipline. He is a past treasurer of the United Kingdom Environmental Mutagen Society (UKEMS) and is currently serving as Vice President. He is also treasurer of the European Environmental Mutagen Society.

Professionally, Prof. Lynch has co-supervised 3 PhD students, numerous MSc/Industrial placement students and published over 40 manuscripts, reviews and book chapters on various aspects of Genetic Toxicology, Mutagenesis and Carcinogenesis. He was appointed Professor (Honorary) in the College of Medicine at Swansea University in 2011.

Declaration of Interests

Personal Interest		Non-personal Interest	
Company	Interest	Company	Interest
GlaxoSmithKline	Employee	NONE	NONE
	Share-holder		